| RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist KG McLure, EM Gesner, L Tsujikawa, OA Kharenko, S Attwell, ... PloS one 8 (12), e83190, 2013 | 154 | 2013 |
| Metal-induced folding of a designed metalloprotein OA Kharenko, MY Ogawa Journal of inorganic biochemistry 98 (11), 1971-1974, 2004 | 65 | 2004 |
| Cu(I) Luminescence from the Tetranuclear Cu4S4 Cofactor of a Synthetic 4-Helix Bundle OA Kharenko, DC Kennedy, B Demeler, MJ Maroney, MY Ogawa Journal of the American Chemical Society 127 (21), 7678-7679, 2005 | 54 | 2005 |
| Incorporating electron-transfer functionality into synthetic metalloproteins from the bottom-up J Hong, OA Kharenko, MY Ogawa Inorganic chemistry 45 (25), 9974-9984, 2006 | 34 | 2006 |
| RVX-297-a novel BD2 selective inhibitor of BET bromodomains OA Kharenko, EM Gesner, RG Patel, K Norek, A White, E Fontano, ... Biochemical and biophysical research communications 477 (1), 62-67, 2016 | 31 | 2016 |
| Discovery of a new chemical series of BRD4 (1) inhibitors using protein-ligand docking and structure-guided design BC Duffy, S Liu, GS Martin, R Wang, MM Hsia, H Zhao, C Guo, M Ellis, ... Bioorganic & Medicinal Chemistry Letters 25 (14), 2818-2823, 2015 | 22 | 2015 |
| Abscisic acid metabolism and lipid accumulation of a cell suspension culture of Lesquerella fendleri OA Kharenko, LI Zaharia, M Giblin, V Čekić, DC Taylor, CD Palmer, ... Plant Cell, Tissue and Organ Culture (PCTOC) 105 (3), 415-422, 2011 | 21 | 2011 |
| Evidence that a miniature CuI metalloprotein undergoes collisional electron transfer in the inverted Marcus region J Hong, OA Kharenko, J Fan, F Xie, AK Petros, BR Gibney, MY Ogawa Angewandte Chemie International Edition 45 (37), 6137-6140, 2006 | 21 | 2006 |
| Molecular mechanisms in the activation of abscisic acid receptor PYR1 L Dorosh, OA Kharenko, N Rajagopalan, MC Loewen, M Stepanova PLoS Comput Biol 9 (6), e1003114, 2013 | 19 | 2013 |
| Design and characterization of novel covalent bromodomain and extra-terminal domain (BET) inhibitors targeting a methionine OA Kharenko, RG Patel, SD Brown, C Calosing, A White, ... Journal of medicinal chemistry 61 (18), 8202-8211, 2018 | 18 | 2018 |
| Identification and characterization of interactions between abscisic acid and mitochondrial adenine nucleotide translocators OA Kharenko, J Boyd, KM Nelson, SR Abrams, MC Loewen Biochemical Journal 437 (1), 117-123, 2011 | 17 | 2011 |
| Electron-transfer functionality of synthetic coiled-coil metalloproteins MY Ogawa, J Fan, A Fedorova, J Hong, OA Kharenko, AY Kornilova, ... Journal of the Brazilian Chemical Society 17 (8), 1516-1521, 2006 | 12 | 2006 |
| Identification and characterization of interactions between abscisic acid and human heat shock protein 70 family members OA Kharenko, D Polichuk, KM Nelson, SR Abrams, MC Loewen The Journal of Biochemistry 154 (4), 383-391, 2013 | 11 | 2013 |
| Novel approaches to targeting BRD4 OA Kharenko, HC Hansen Drug Discovery Today: Technologies 24, 19-24, 2017 | 10 | 2017 |
| Abscisic acid binds to recombinant Arabidopsis thaliana G-protein coupled receptor-type G-protein 1 in Sacaromycese cerevisiae and in vitro OA Kharenko, P Choudhary, MC Loewen Plant physiology and biochemistry 68, 32-36, 2013 | 9 | 2013 |
| Abstract C86: The clinical candidate ZEN-3694, a novel BET bromodomain inhibitor, is efficacious in the treatment of a variety of solid tumor and hematological malignancies … S Attwell, E Campeau, R Jahagirdar, O Kharenko, K Norek, L Tsujikawa, ... Molecular Cancer Therapeutics 14 (12 Supplement 2), C86-C86, 2015 | 4 | 2015 |
| Preclinical characterization of ZEN-3694, a novel BET bromodomain inhibitor entering phase I studies for metastatic castration-resistant prostate cancer (mCRPC) S Attwell, R Jahagirdar, K Norek, C Calosing, L Tsujikawa, OA Kharenko, ... CANCER RESEARCH 76, 2016 | 3 | 2016 |
| Abstract LB-207: Preclinical characterization of ZEN-3694, a novel BET bromodomain inhibitor entering phase I studies for metastatic castration-resistant prostate cancer (mCRPC) S Attwell, R Jahagirdar, K Norek, C Calosing, L Tsujikawa, OA Kharenko, ... Cancer research 76 (14 Supplement), LB-207-LB-207, 2016 | 2 | 2016 |
| Abstract LB-92: RVX-2135 is a novel, orally bioavailable epigenetic BET inhibitor that synergizes with cytarabine and idarubicin to inhibit proliferation of acute myeloid … E Campeau, R Jahagirdar, J Wu, EM Gesner, O Kharenko, R Yu, S Attwell, ... Cancer Research 73 (8 Supplement), LB-92-LB-92, 2013 | 2 | 2013 |
| Characterization of the ATP-translocating properties of the predicted Arabidopsis thaliana mitochondrial adenine nucleotide translocator 2 OA Kharenko, MC Loewen Botany 88 (7), 685-690, 2010 | 2 | 2010 |
